Member Contact: Dr Jai Rautela
Position: Chief Scientific Officer, Co-Founder
Industry: Biotech & Pharmaceuticals
oNKo-innate is a discovery stage company that specialises in therapies aimed at stimulating an innate immune response against cancer.
Our major focus is the development of novel first-in-class drugs that boost the ability of natural killer (NK) cells to eliminate cancer. Many of our candidates have the potential to be stand-alone immunotherapies or used in combination with leading checkpoint inhibitors to induce broader and more effective anti-cancer immunity. Our competitive advantage in this area results from our scientific advisory board members being among the foremost experts in NK cell biology, immunotherapy, apoptosis and chemical biology. Driven by improving patient outcomes, we are developing the next generation of cancer immunotherapies.